David R. Head

Hematology

3601 21st Ave S
Nashville, TN 37232

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Multiplex imaging reveals spatially resolved DNA-damage response neighborhoods in TP53-mutated myelodysplastic neoplasms.

Multiplex imaging reveals spatially resolved DNA-damage response neighborhoods in TP53-mutated myelodysplastic neoplasms.

Journal: The Journal of pathology

Published: November 26, 2023

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: February 07, 2022

Primary central nervous system erythroid sarcoma with NFIA-CBFA2T3 translocation: A rare but distinct clinicopathologic entity.

Primary central nervous system erythroid sarcoma with NFIA-CBFA2T3 translocation: A rare but distinct clinicopathologic entity.

Journal: American journal of hematology

Published: July 13, 2020

Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431.

Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431.

Journal: Archives of pathology & laboratory medicine

Published: August 21, 2019

Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.

Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.

Journal: Leukemia research

Published: August 03, 2017

Acute autoimmune hemolytic anemia due to anti-Ena autoantibody successfully treated with rituximab.

Acute autoimmune hemolytic anemia due to anti-Ena autoantibody successfully treated with rituximab.

Journal: Transfusion

Published: March 30, 2017

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.

Journal: Blood

Published: January 24, 2017

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: January 02, 2017

Data-Driven Iterative Refinement of Bone Marrow Testing Protocols Leads to Progressive Improvement in Cytogenetic and Molecular Test Utilization.

Data-Driven Iterative Refinement of Bone Marrow Testing Protocols Leads to Progressive Improvement in Cytogenetic and Molecular Test Utilization.

Journal: American journal of clinical pathology

Published: October 23, 2016

Myelodysplastic syndromes, version 2.2015.

Myelodysplastic syndromes, version 2.2015.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 05, 2015

PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: the missing link supporting a stem cell origin.

PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: the missing link supporting a stem cell origin.

Journal: Haematologica

Published: June 22, 2014

Myelodysplastic syndromes: clinical practice guidelines in oncology.

Myelodysplastic syndromes: clinical practice guidelines in oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: July 13, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026